Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2014-12-23 Remuneration Information
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Exercise of employee share options
Remuneration Information Classification · 99% confidence The document explicitly details the exercise of employee share options by the CEO, Kjetil Hestdal, on December 23rd, 2014. It specifies the number of options exercised, the strike price, and the resulting share and option holdings. This type of transaction, involving personal share transactions by company directors/executives (insider trades) resulting from option exercises, directly aligns with the definition of 'Director's Dealing' (DIRS). Although it involves shares, it is not a general share issue (SHA) or a buyback (POS), but a report of an insider's transaction.
2014-12-23 English
Photocure ASA - 2014 business performance goals update
Earnings Release Classification · 98% confidence The document is titled "Photocure ASA - 2014 business performance goals update" and provides an update on sales, financial performance, pipeline progress (Hexvix/Cysview, Visonac, Cevira), and cash position as of December 22, 2014. It is a periodic update on business performance and financial outlook, but it is not a full, comprehensive financial report like a 10-K or IR. It is also not a formal Earnings Release (ER) which typically focuses only on the final reported numbers for a period. Since it provides a detailed operational and financial update outside of a standard quarterly/annual report structure, and is not a transcript, presentation, or formal regulatory filing announcement, it best fits the category of a Management Report (MDA) or potentially an Investor Presentation (IP) if it were slide-based. Given the narrative structure detailing business segments, progress, and outlook, MDA is the most appropriate fit for this type of performance update/review. FY 2014
2014-12-22 English
Financial calendar
Report Publication Announcement Classification · 100% confidence The document is titled 'Financial calendar' and lists future dates for various corporate events, including 'Quarterly Report' releases and the 'Annual General Meeting'. It is not the report itself, but rather an announcement detailing the schedule of future corporate publications and events. Since it is a schedule announcement and not a specific regulatory filing type like 10-K or IR, and it doesn't fit the definitions for DIV, DVA, or MANG, the most appropriate classification is Report Publication Announcement (RPA), as it announces when reports will be published, or RNS if RPA is too specific. Given the context of announcing future report dates, RPA is a strong fit, but since it also lists the AGM date, it is a general corporate schedule announcement. Given the options, and the fact that it announces the publication schedule for reports, RPA is the best fit, although RNS is a possibility if RPA is interpreted too narrowly. However, RPA specifically covers announcements regarding the timing/release of reports. I will select RPA.
2014-12-08 English
Photocure: Cevira® data published in American Journal of Obstetrics & Gynecology
Regulatory Filings Classification · 95% confidence The document is a press release from Photocure ASA announcing that the Phase 2b study results for their product Cevira have been published in the American Journal of Obstetrics & Gynecology. It details clinical findings, quotes management and investigators, and provides contact information. This type of announcement, which reports on a specific event (publication of data) rather than being a comprehensive periodic report (like 10-K or IR) or a general regulatory filing, fits best under the 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially an 'Investor Presentation' (IP) if it were a slide deck, but since it's a news release about data, RNS is the most appropriate general category for non-standard announcements not covered by other specific codes. Given the options, it is a general corporate announcement/news release about a significant event, which often defaults to RNS if not specifically an ER, DIV, or CAP announcement. It is not a full report, a transcript, or a management discussion.
2014-11-04 English
Photocure ASA: Presentation of the third quarter 2014 results
Investor Presentation Classification · 95% confidence The document explicitly states it is a 'Presentation of the third quarter 2014 results' and provides details about when and where this presentation will occur (date, time, location, webcast links). This indicates an announcement about an upcoming investor event where results will be discussed. Since the text is short and focuses on announcing the event rather than containing the full financial report or the transcript of the call itself, it aligns best with an Investor Presentation (IP) announcement or, more generally, a Report Publication Announcement (RPA) if the presentation material itself is the primary focus being announced. Given the context of 'Presentation of the third quarter results,' it is highly likely this document is announcing the availability of the presentation slides/materials. The definition for Investor Presentation (IP) is 'Detailed presentation for investors focusing on financials, strategy, and market position.' This announcement is directly about that presentation. If the document were the actual presentation slides, IP would be correct. If it were just a brief notice that the Q3 report is out, RPA might fit. Since it details the presentation event for the Q3 results, IP is the most specific fit for the content being presented, even if this specific text is the announcement of that presentation.
2014-10-28 English
Photocure: Expert consensus on the optimal use of Cysview® BLC published in Nature Reviews Urology
Earnings Release Classification · 92% confidence The document is a press release from Photocure ASA announcing that an expert consensus statement regarding the use of their product, Cysview®, has been published in Nature Reviews Urology. It details the findings and implications of this expert review for managing Bladder Cancer. This type of announcement, which publicizes the release of expert opinions, clinical data, or research findings, is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a formal slide deck. However, since it is a news announcement about external expert validation being published, and it doesn't fit the specific definitions for ER, IR, 10-K, or MDA, the most appropriate general category for a corporate announcement of this nature that isn't a direct financial report or a specific corporate action (like dividend or management change) is Regulatory Filings (RNS), which serves as a broad category for important corporate news releases not covered elsewhere. Given the context of a specialty pharma company announcing validation of its technology, RNS is the best fit among the provided options for a general news release. Q3 2014
2014-09-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.